Abstract
Resmetirom is marketed under the brand name of Rezdiffra which is FDA-approved for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
Present disclosure describes the different crystalline forms of Resmetirom.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Anonymous, "Crystalline forms of Resmetirom and processes for preparation thereof", Technical Disclosure Commons, (February 12, 2025)
https://www.tdcommons.org/dpubs_series/7832
COinS